SAB Biotherapeutics Inc. (SABS), a clinical-stage biopharmaceutical company, on Tuesday announced positive topline data from its Phase 1 trial of SAB-142, a potential disease-modifying therapy for Type 1 Diabetes.
The trial, conducted among healthy volunteers, met its primary objectives related to safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics.
SAB-142, a human anti-thymocyte immunoglobulin or hIgG, demonstrated a favorable safety profile with no reports of serum sickness or anti-drug antibodies at the target dose.
The drug also showed sustained immunomodulation and a mechanism of action analogous to rabbit ATG, suggesting significant potential in delaying or preventing the progression of T1D.
SAB Biotherapeutics plans to advance SAB-142 into Phase 2b clinical trials in 2025, focusing on adult and pediatric patients with new-onset Type 1 Diabetes.
The company will present full details of these promising results during an R&D webinar today, January 28, 2025, at 8:00 a.m. ET.As of September 30, 2024, SAB had cash, cash equivalents, and available-for-sale securities of $30.4 million.
The company expects that additional funds from the exercise of outstanding Tranche B warrants will provide sufficient cash to support its operations through 2026.
SABS closed Monday's (Jan.27 2025) trading at $4.36 up 6.34%. In premarket trading Tuesday, the stock is down 22.01% at $3.40.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.